Abstract

Last year subcutaneous sumatriptan (Imigran – Glaxo) was introduced in Britain as “a revolutionary acute therapy in migraine”. The claims were repeated when an oral preparation was launched earlier this year. Sumatriptan is licensed for the acute relief of migraine attacks with or without aura; the subcutaneous preparation is also licensed for the treatment of cluster headache.